Efficacy News and Research

RSS

Hypertension drug market to decrease through 2013 due to generic erosion and few emerging therapies

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to extensive generic erosion, the hypertension drug market will be constrained through 2018 by a pipeline containing very few emerging therapies with novel mechanisms of action. Gilead's darusentan was positioned to be the next emerging therapy with a novel mechanism of action to reach the hypertension market. However, following darusentan's failure to meet its primary endpoint in the recent DORADO-AC Phase III clinical trial, further development of the agent has been terminated.

3 Feb 2010

MV vaccine prevents TB in people with HIV infection

Results from clinical trials conducted in Tanzania show that a new vaccine against tuberculosis, Mycobacterium vaccae (MV), is effective in preventing tuberculosis in people with HIV infection. Findings from the trials, which were conducted by investigators from Dartmouth Medical School in the United States, will be published in the next issue of AIDS, the leading journal in the field of HIV and AIDS research. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

3 Feb 2010

Promising results from Soligenix' RiVax vaccine trials against ricin toxin

Soligenix, Inc., a late-stage biotechnology company, announced today the publication of an article in the February 2010 edition of Vaccine, which describes preclinical formulations of RiVax™, its ricin toxin vaccine, with heightened stability. The article was authored by the Company's collaborators at the University of Texas Southwestern Medical Center at Dallas (UT Southwestern) where the vaccine originated. RiVax™ is currently being evaluated in Phase 1 human safety and immunogenicity trials, as well as non-human primate trials for efficacy.

3 Feb 2010

Repros Therapeutics receives FDA confirmation for initiating Androxal IND

Repros Therapeutics Inc. today announced that the Company has received verbal confirmation from the Division of Metabolic and Endocrine Drug Products of the Food and Drug Agency that the Company may initiate its Investigational New Drug Application for the study of oral Androxal® in the treatment of hypogonadal men with Type II Diabetes (T2D) with a Phase IIa trial.

3 Feb 2010

Artefill could be viable for lipoatrophy and non-surgical anti-aging enhancement

Suneva Medical, a privately-held aesthetic medical device company, today announced that two clinical studies suggest Artefill may be a safe, effective, long-term treatment option for age-related and HIV lipoatrophy patients.

3 Feb 2010

CSC, ALS TDI extend collaboration in advancing potential stem cell therapy for ALS

California Stem Cell, Inc. (CSC) and ALS Therapy Development Institute (ALS TDI) are pleased to announce an extension and expansion of their collaboration aimed at advancing a potential stem cell therapy for ALS (amyotrophic lateral sclerosis). This effort will build on work that has already been completed as part of this on-going partnership to understand how stem cells, and their derivatives, may be applied to treatment of this fatal neurodegenerative disease.

3 Feb 2010

Celsis IVT alleges patent infringement, files lawsuit against Sekisui Chemical and subsidiaries

Celsis In Vitro, Inc. announced today that it has filed a patent infringement lawsuit against XenoTech LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in the United States District Court for the Northern District of Illinois in Chicago. XenoTech and Sekisui Medical are wholly-owned subsidiaries of Sekisui Chemical.

3 Feb 2010

Hovione announces filing of new drug application in Japan for the influenza drug CS-8958

Hovione is announcing the filing of a new drug application in Japan by its licensee Daiichi Sankyo Company Ltd. for the influenza drug CS-8958, which is delivered using Hovione's TwinCaps(R) inhaler.

2 Feb 2010

Javelin Pharmaceuticals' NDA for Dyloject Injection accepted for formal review

Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, has been accepted for formal review.

2 Feb 2010

Medco Health Solutions acquires DNA Direct

Committed to being at the forefront of translating personalized medicine from the science to its daily practice in healthcare, Medco Health Solutions, Inc. today announced the acquisition of DNA Direct, Inc., a leader in providing guidance and decision support for genomic medicine to patients, providers, payors and employees.

2 Feb 2010

Overview of newly evolving technologies for diagnosing and monitoring HIV infections

Rising consumer awareness that early diagnosis and treatment can delay the progression of human immunodeficiency virus (HIV) to anti-immuno deficiency syndrome (AIDS) has had a telling impact on the sales of HIV tests.

2 Feb 2010

Decision Resources: Benlysta to garner more than $500M in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, following its expected regulatory approval in 2011 in the United States and Europe, Human Genome Sciences/GlaxoSmithKline's Benlysta will garner sales of more than $500 million in 2018 in the systemic lupus erythematosus drug market.

2 Feb 2010

Pervasis Therapeutics reaches agreement with FDA on pivotal Phase 3 clinical trial for Vascugel

Pervasis Therapeutics, Inc. today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of a pivotal Phase 3 clinical trial for Vascugel®, an investigational new drug for the prevention of hemodialysis access graft failure.

2 Feb 2010

YM BioSciences-Cytopia merger complete

YM BioSciences Inc., announced that the merger of Cytopia Limited, the Australian biopharmaceutical company, into YM under a Scheme of Arrangement, has been concluded.

1 Feb 2010

Ipsen reports consolidated group sales of €1,032.8M for 2009

Ipsen reported today its sales for the fourth quarter and full year 2009.

1 Feb 2010

WHO pneumonia expert honored with PACE Global Leadership Award

WHO pneumonia expert Dr. Thomas Cherian will be honored by a group of the world’s leading infectious disease experts today for his pivotal work to accelerate access to vaccines preventing pneumococcal disease, the world’s leading vaccine-preventable killer of children under age five.

31 Jan 2010

FDA approved 53 new oncology and hematology drugs between 2005 and 2007

Over a two and half year period, beginning in 2005 when the U.S. Food and Drug Administration's oncology drug product's office began reviewing marketing applications, a total of 60 new oncology and hematology drugs were reviewed, of which 53 were approved, according to a new article published online January 29 in the Journal of the National Cancer Institute.

30 Jan 2010

Congressman Rothman secures 1.49M in federal dollars for EHMC's bloodless medicine program

Congressman Steve Rothman (D-NJ) will be the featured speaker at Englewood Hospital and Medical Center today, 1:00-2:00 pm. Congressman Rothman will announce the latest batch of federal funds, $1.49 million, for the Institute for Patient Blood Management and Bloodless Medicine and Surgery. This brings the total amount of federal funding secured by Congressman Rothman for this institute to $4.69 million in federal resources and to over six million dollars to Hospital programs since 2002.

30 Jan 2010

New vaccine effective in preventing TB in HIV patients

Investigators from Dartmouth Medical School (DMS) have reported results of a clinical trial showing that a new vaccine against tuberculosis, Mycobacterium vaccae (MV), is effective in preventing tuberculosis in people with HIV infection.

30 Jan 2010

ConjuChem Biotechnologies reports financial results for fiscal year ended October 31, 2009

The Company's net loss for the quarter ended October 31, 2009 amounted to $2.5 million or ($0.01) per share, compared to $10.9 million or ($0.04) per share, for the quarter ended October 31, 2008.

29 Jan 2010

Efficacy News and Research

Hypertension drug market to decrease through 2013 due to generic erosion and few emerging therapies

MV vaccine prevents TB in people with HIV infection

Promising results from Soligenix' RiVax vaccine trials against ricin toxin

Repros Therapeutics receives FDA confirmation for initiating Androxal IND

Artefill could be viable for lipoatrophy and non-surgical anti-aging enhancement

CSC, ALS TDI extend collaboration in advancing potential stem cell therapy for ALS

Celsis IVT alleges patent infringement, files lawsuit against Sekisui Chemical and subsidiaries

Hovione announces filing of new drug application in Japan for the influenza drug CS-8958

Javelin Pharmaceuticals' NDA for Dyloject Injection accepted for formal review

Medco Health Solutions acquires DNA Direct

Overview of newly evolving technologies for diagnosing and monitoring HIV infections

Decision Resources: Benlysta to garner more than $500M in 2018

Pervasis Therapeutics reaches agreement with FDA on pivotal Phase 3 clinical trial for Vascugel

YM BioSciences-Cytopia merger complete

Ipsen reports consolidated group sales of €1,032.8M for 2009

WHO pneumonia expert honored with PACE Global Leadership Award

FDA approved 53 new oncology and hematology drugs between 2005 and 2007

Congressman Rothman secures 1.49M in federal dollars for EHMC's bloodless medicine program

New vaccine effective in preventing TB in HIV patients

ConjuChem Biotechnologies reports financial results for fiscal year ended October 31, 2009

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News